-
Mashup Score: 0Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review | Immunotherapy - 10 month(s) ago
We present a case of a 76-year-old patient with recurrent cervical cancer who underwent first-line treatment with penpulimab combined with anlotinib. The patient was diagnosed with poorly differentiated stage III C1r cervical squamous cell carcinoma and received standard cisplatin-sensitized chemoradiotherapy, subsequently achieving a good treatment effect of complete response. Recurrence…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Cancer immunotherapy via stem cell-derived NK cells | Immunotherapy - 10 month(s) ago
NK cells are the first sentinels of the immune system that can recognize and eradicate transformed cells. Their activation without a need for additional signaling have attracted great attention on the use of NK cells as a promising option in cancer immunotherapy. However, the large-scale production of NK cells for successful NK cells therapy is a challenge that needs to be tackled. Engineering NK…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#NKCells captured many research groups’ attention for immunotherapy applications. This review discusses recent advances in #StemCells derived NKs and NKs engineering for clinical applications in cancer NK-based therapy and prospects #NKCancerTherapy https://t.co/vqohshZxzI
-
-
Mashup Score: 0A meta-analysis of application of PD-1/PD-L1 inhibitor-based immunotherapy in unresectable locally advanced triple-negative breast cancer | Immunotherapy - 10 month(s) ago
Aims: The purpose of this study was to explore the efficacy of immunotherapy for patients with triple-negative breast cancer (TNBC). Materials & methods: Randomized clinical trials comparing immunotherapy with chemotherapy for advanced TNBC patients were included. Results: A total of six articles (3183 patients) were eligible for this meta-analysis. PD-1/PD-L1 inhibitor-based immunotherapy…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Immunotherapy with PD-1/L1 inhibitor combined with chemotherapy can achieve a better effect, prolong PFS and improve remission rate in local advanced or metastatic triple-negative BC compared with chemotherapy Read the Open Access Met-Analysis: https://t.co/1YlsgQKNlf
-
-
Mashup Score: 0Lessons from the diagnosis and treatment of severe immune checkpoint inhibitor-associated pneumonia: a case report | Immunotherapy - 10 month(s) ago
Herein, we report a case of an elderly male patient who underwent extended radical resection of cardiac carcinoma after regular chemotherapy combined with sintilimab (PD-1 monoclonal antibody) immunotherapy complicated with severe pneumonitis postoperatively. We performed several treatments for aspiration pneumonitis; however, the patient’s pulmonary infection and oxygenation were not efficiently…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Case report looking at an elderly #CardiacCarcinoma patient who developed severe #pneumonitis post-surgery. Modified treatment for #ICI-associated pneumonitis effectively controlled inflammation and improved oxygenation Read the full Open Access article: https://t.co/QqZR0OJMiv
-
-
Mashup Score: 0Enhanced binding at fever temperatures of HER2 in complex with trastuzumab and pertuzumab | Immunotherapy - 10 month(s) ago
Aim: Fever follows the administration of trastuzumab and pertuzumab used in HER2-relevant immunotherapy, but is often eliminated in clinical practice. This work explores the role of temperature (37–39°C) in the formation of immune complexes between HER2 with either trastuzumab or pertuzumab or with both antibodies. Materials & methods: Using molecular dynamics simulations and free energy…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Research article by Singh and Stan shows febrile temperatures boost #trastuzumab and #pertuzumab activity, enhancing tumor targeting. Important findings as fevers are typically eliminated during treatment #BreastCancer #FeverTherapy https://t.co/OTABZbOloi
-
-
Mashup Score: 0Evaluation of appendectomy as a potential risk factor for immune checkpoint inhibitor-associated enterocolitis | Immunotherapy - 10 month(s) ago
Aims: The relationship between appendectomy and immune checkpoint inhibitor (ICI) enterocolitis was explored. Methods: Patients who began ICIs between July 2010 and September 2020 (n = 10,907) were included. The exposure group included patients with evidence of appendectomy prior to ICIs in operative notes (n = 380). The control group included patients with evidence of normal appendix in…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New research article compared #ICI-related #GutInflammation rates in patients with and without prior #appendectomy. Surprisingly, rates were similar, indicating that appendectomy may not reduce gut inflammation caused by ICIs Read the article online: https://t.co/Npia7jcLSG
-
-
Mashup Score: 0Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers | Immunotherapy - 10 month(s) ago
The impact of checkpoint inhibitors on gastroesophageal cancer treatment has been tremendous in the last 2 years. KEYNOTE-590, CHECKMATE 649 and CheckMate 648 are landmark trials that have introduced immunotherapy to the field as first-line therapy, leading to a paradigm change for advanced esophageal and gastric cancer. Chemotherapy in combination with immunotherapy is now the standard of care…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Review article assessing combined #ICIs and #chemotherapy, leading to improved response rates and extended survival. PD-L1 Combined Positive Score helps identify effective candidates. Challenges remain, highlighting the need for further research https://t.co/kNzqKU2dmx
-
-
Mashup Score: 0Gastrointestinal treatment-related adverse events of combined immune checkpoint inhibitors: a meta-analysis | Immunotherapy - 10 month(s) ago
Introduction: Combined immune checkpoint inhibitors can cause gastrointestinal adverse events. Methods: We performed a meta-analysis of pooled colonic, hepatic and pancreatic treatment-related adverse events of combined ICI. Results: 53 trials reporting treatment-related adverse events in 6581 patients. All grade diarrhea was the most common adverse event seen in 25.4% patients, followed by all…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Meta-Analysis by @RahulKarnaMD @DouglasAdlerMD @BabuPMohan2 @SmitDeliwalaMD demonstrating a high incidence of all grades and ≥ 3 grade GI adverse events. Read online now: https://t.co/BjghB5uVAC
-
-
Mashup Score: 0Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis | Immunotherapy - 10 month(s) ago
Objective: Evaluate the potency of anti-PD-1/PD-L1 antibodies in advanced gastroesophageal cancer patients with different clinical features. Methods: Randomized, controlled trials comparing anti-PD-1/PD-L1 antibodies with chemotherapy in individuals with gastroesophageal cancer were retrieved. Results: 15 trials involving 9194 individuals were included. PD-1/PD-L1 inhibitors significantly…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
PD-1/PD-L1 inhibitor improved OS in #AdvancedGastroesophagealCarcinoma, especially in patients with #EsophagealCancer. The race, primary tumor sites, and PD-L1 CPS can be used to predict the potency of #ICIs Meta-Analysis paper online now: https://t.co/rrEDTKnMui
-
-
Mashup Score: 0Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis | Immunotherapy - 10 month(s) ago
Aim: To evaluate the efficacy and safety of first-line immunochemotherapy in the treatment of advanced esophageal squamous cell carcinoma (CRD42021287033). Methods: PubMed, Embase, Cochrane Library and Web of Science were systematically searched to obtain randomized controlled trials, and the outcome indicators of the reports were compared and analyzed. Results: A total of 3163 patients from five…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exciting meta-analysis findings on first-line immunochemotherapy for advanced esophageal squamous cell carcinoma! Discovering the efficacy and safety of this cutting-edge treatment approach. #EsophagealCancer #Immunotherapy https://t.co/phNQo63ubQ
-
Open Access case report of recurrent cervical cancer treatment with #penpulimab + #anlotinib after prior therapy. Despite brain and lung metastases, this combination showed remarkable curative effect for over 17 months #CervicalCancer #Immunotherapy https://t.co/KnkLzZUAkk